Why it matters

InductiveHealth Informatics is making a major lobbying comeback after a year-long hiatus. The health tech company spent $90,000 with Arnold & Porter in 2023 before going dark. Now they’re back with BGR Government Affairs and three seasoned lobbyists focused on disease surveillance tech.

By the numbers

Previous spending: $90,000 with Arnold & Porter Kaye Scholer LLP in 2023 (peak of $50,000 in Q2)

New lobbying team: Three experienced lobbyists at BGR Government Affairs LLC

  • Marvin B. Figueroa: 20+ years experience, healthcare specialist
  • Christopher P. Kelly: Similar portfolio, focuses on health insurance and federal programs
  • Robert D. Walton: Deep health systems experience

BGR’s scale: $37.5 million annual revenue, 180+ clients

Why now

Multiple disease threats are creating urgency around surveillance technology. H5N1 bird flu spread to dairy cows in March 2024, marking unprecedented mammal transmission. The WHO declared a new mpox public health emergency in August 2024. These crises highlight gaps in current monitoring systems that InductiveHealth’s technology could address.

The agenda

InductiveHealth previously lobbied on the Pandemic All-Hazards Preparedness Act reauthorization and disease surveillance funding. Current congressional activity includes the SEWER Act for national wastewater surveillance and the BITE Act for AI-enhanced disease monitoring systems.

Competitive landscape

BGR represents multiple health tech firms in similar spaces. bioMérieux Inc. focuses on diagnostic testing. Real Time Medical Systems LLC works on healthcare data systems. This creates potential coalition opportunities but also internal competition for the firm’s attention.

Between the lines

Congress approved a historic $10.5 billion increase for pandemic preparedness in FY2025. The CDC’s budget jumped nearly $500 million to $9.683 billion. InductiveHealth is positioning itself as these massive appropriations get deployed. Their timing coincides with legislative momentum around surveillance modernization.

The bottom line

InductiveHealth is betting big on surveillance technology demand. After sitting out 2024, they’re back with heavyweight representation just as Congress opens the funding spigots for pandemic preparedness tech.

Spot something wrong? Report an issue with this article